Inflammation-associated diseases encompass a range of infectious diseases and non-
infectious inflammatory diseases, which continuously pose one of the most serious threats to …

Oral administration is the preferred route of drug delivery in clinical practice due to its
noninvasiveness, safety, convenience, and high patient compliance. The gastrointestinal …

The oral delivery of nano-drug delivery systems (Nano-DDS) remains a challenge. Taking
inspirations from viruses, here we construct core–shell mesoporous silica nanoparticles …

The lymphatic system has garnered significant attention in drug delivery research due to the
advantages it offers, such as enhancing systemic exposure and enabling lymph node …

The epithelial mucosa is a key biological barrier faced by gastrointestinal, intraoral,
intranasal, ocular, and vaginal drug delivery. Ligand-modified nanoparticles demonstrate …

The era of RNA medicine has become a reality with the success of messenger RNA (mRNA)
vaccines against COVID-19 and the approval of several RNA interference (RNAi) agents in …

An up-to-date overview of the current state of the art of polysaccharide-based spherical
particles as carriers of active/bioactive substances, with a particular emphasis on their …

Strong precorneal clearance mechanisms including reflex blink, constant tear drainage, and
rapid mucus turnover constitute great challenges for eye drops for effective drug delivery to …

Ligand-modified nanocarriers can promote oral or inhalative administration of
macromolecular drugs across the intestinal or pulmonary mucosa. However, enhancing the …

Mucus clearance, epithelium mucosal barrier and P-glycoprotein (P-gp) efflux are the main
gastrointestinal barriers that limit the oral delivery of nanoparticles. Inspired by tunable …